CJC-1295 + Ipamorelin vs IGF-1 LR3: What Is the Difference?
One pair asks the body to make its own growth signal. The other is the growth signal itself. That is upstream versus downstream.
In plain English
CJC-1295 with Ipamorelin is a two-part preparation studied for prompting the pituitary gland to release growth hormone. The two components work through different receptors, which is why they are paired.
IGF-1 LR3 is a modified version of insulin-like growth factor 1 — one of the signals the body produces downstream of growth hormone, engineered to avoid being captured by carrier proteins.
The difference, without the jargon
Picture a chain of command. CJC-1295 and Ipamorelin act near the top, on the gland that releases growth hormone. IGF-1 LR3 sits further down the chain — it is one of the messengers produced after growth hormone has already done its part. So research using the first is asking questions about the signalling system itself, while research using the second skips the system and works with the downstream messenger directly. There is a practical gap too. The CJC/Ipamorelin combination is a blend of two short peptides that dissolve easily, though its lab report needs to identify both parts and state their ratio. IGF-1 LR3 is a folded protein: it needs acidic liquid to dissolve, cannot be frozen and thawed repeatedly, and typically has a protein additive included to stop it sticking to the container.
Common questions
What is the difference between CJC-1295 + Ipamorelin and IGF-1 LR3?
CJC-1295 and Ipamorelin are studied for prompting the release of growth hormone from the pituitary gland. IGF-1 LR3 is a modified version of a signal produced downstream of growth hormone. One acts on the system; the other is a product of it.
Why are CJC-1295 and Ipamorelin sold together?
They act on two different receptors that both lead to growth hormone release, so pairing them recruits two routes instead of one. It is a combination by design, not two versions of the same thing.
What makes Ipamorelin different from older compounds in this class?
Earlier compounds also triggered the release of other hormones such as cortisol and prolactin, which muddies any experiment where growth hormone is the thing being measured. Ipamorelin was designed to avoid that, giving cleaner results.
Technical reference below
How they actually differ
Comparing the two: CJC-1295 + Ipamorelin is combination — ghrh(1-29) analogue plus selective ghrelin-receptor agonist, while IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1 — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution); their leading degradation routes differ (independent degradation of the two components at different rates, which is the defining stability characteristic of any blend. for CJC-1295 + Ipamorelin, denaturation and aggregation for IGF-1 LR3), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 + Ipamorelin — origin
This is a two-compound blend studied for complementary mechanisms rather than a single molecule. CJC-1295 is a modified GHRH(1-29) fragment with four amino-acid substitutions that resist enzymatic degradation. Ipamorelin is a pentapeptide ghrelin-receptor agonist notable for its selectivity — it was specifically developed to stimulate GH release without the cortisol and prolactin effects of earlier secretagogues like GHRP-6.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
CJC-1295 + Ipamorelin research themes
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
CJC-1295 + Ipamorelin handling
- Confirm whether the labelled mass is total blend mass or per-component before calculating concentration.
- Reconstitute the full vial rather than attempting to subdivide dry material — the two components will not partition evenly in powder form.
- Protect from light and refrigerate.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Both third-party tested
Every Popular Peptides batch of CJC-1295 + Ipamorelin and IGF-1 LR3 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 + Ipamorelin reference
Related comparisons
CJC-1295 + Ipamorelin and IGF-1 LR3 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.